Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

63.93
353,481

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 5.88% and 1.63%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 0% and 37.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing

by Zacks Equity Research

Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.

Mirati (MRTX) Down 17.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

by Zacks Equity Research

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

by Zacks Equity Research

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.

Mirati (MRTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 8.36% and 41.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?

by Zacks Equity Research

Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?

by Zacks Equity Research

Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.

Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

by Zacks Equity Research

Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy designation to Mirati's (MRTX) Krazati (adagrasib) for treating patients with advanced, KRAS-mutated colorectal cancer.

Company News for Dec 14, 2022

by Zacks Equity Research

Companies in The News Are:PLAB,CNB,BA,UAL,MRTX

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

by Zacks Equity Research

The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling cohort of the KRYSTAL-1 study.

Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib

by Zacks Equity Research

Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.

Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

by Zacks Equity Research

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.

Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark. Stock rises in after-hours trading.

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.